Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Ruggeri
E M
EM
Department of Medical Oncology, Ospedale Belcolle, Viterbo. Electronic address: ruggeriem@yahoo.it.
Cecere
F L
FL
Department of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Moscetti
L
L
Department of Medical Oncology, Ospedale Belcolle, Viterbo.
Doni
L
L
Department of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Padalino
D
D
Department of Medical Oncology, Ospedale Belcolle, Viterbo.
Di Costanzo
F
F
Department of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D011758:Pyrroles / Q000009:adverse effects*; D006435:Renal Dialysis; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000628:therapy; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib